Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04603521 · ClinicalTrials.gov registry record
Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)
A clinical trial of Cardiomyopathy and Obstructive Hypertrophic Cardiomyopathy, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 325
- Enrollment target
- 1
- Study location
NCT04603521 is a study of Cardiomyopathy and Obstructive Hypertrophic Cardiomyopathy that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 325 participants, below the 544-participant average among 25 other Cardiomyopathy trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04603521, a study of Cardiomyopathy and Obstructive Hypertrophic Cardiomyopathy, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 325 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: HCM is a genetic heart disease. It can cause fatigue, chest pain, or even death. For more than 50 years, a surgery called septal myectomy has been used to help people with this disease. Dr. Andrew G. Morrow originated the surgery and performed it more than 200 times at NIH starting in 1960. Researchers want to learn the long-term success of this surgery. Objective: To determine long-term survival at least 35 years after surgical myectomy at NIH and examine data for people who are confirmed to be deceased or alive. Eligibility: People who had surgical myectomy by Dr. Morrow from 1960 to 1983. Design: This study uses images and data that were obtained in the past. Many of the participants are deceased. Most of the others are no longer being followed at the NIH. The medical records of people treated by Dr. Morrow were microfiched. These records can be accessed at the NIH. The records will be searched for keywords to find participants for this study. Participants clinical data, such as lab testing and imaging, will be used. Other data collected as part of the original study will also be used. Researchers will use participants name, date of birth, and Social Security number to learn if they are alive or deceased. If they are deceased, researchers will try to find the age of death. Online databases and search engines will also be used. Survival data will be compared to data from the general U.S. population for the same time period. Data will be stored in a database that is password protected. The study will last about 1 year.
Conditions Studied
Study Locations (1)
Maryland
- National Heart, Lung and Blood Institute (NHLBI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2020-10-20 |
| Est. Completion | 2022-04-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04603521
The ClinicalTrials.gov registry entry for NCT04603521 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 325 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 544-participant average among 25 other Cardiomyopathy trials with a reported enrollment target (40% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cardiomyopathy appearing as the primary indexed condition, and to 0 interventions.
NCT04603521 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04603521 about?
NCT04603521 is a clinical study titled "Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)". Background: HCM is a genetic heart disease. It can cause fatigue, chest pain, or even death. For more than 50 years, a surgery called septal myectomy has been used to help people with this disease. Dr. Andrew G. Morrow originated the surgery and performed it more than 200 times at NIH starting in 1...
What is the current status of trial NCT04603521?
This trial is currently completed. The enrollment target is 325 participants. The study started on 2020-10-20. Estimated completion is 2022-04-26.
What conditions does trial NCT04603521 study?
This clinical trial studies the following conditions: Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy.
Who is sponsoring clinical trial NCT04603521?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04603521 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
RECRUITING
-
Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
RECRUITING · Phase 4
-
Molecular Imaging of Primary Amyloid Cardiomyopathy
RECRUITING · NA
-
Impella Reverse Remodeling in End-Stage Heart Failure
RECRUITING
-
Clinical Course Of Disease In Participants With FA-CM
RECRUITING
-
Genetics of Cardiovascular and Neuromuscular Disease
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.